NCT01704599View on ClinicalTrials.gov

Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

June 30, 2013

Study Completion Date

May 31, 2014

Conditions
Psoriasis
Interventions
DRUG

Humira Then Humira plus 3 B vitamins

Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Wayne State University

OTHER

NCT01704599 - Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter